摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[2-(1,4-diaza-bicyclo[3.2.2]non-4-yl)-pyrimidin-5-yl]-3H-benzo[d][1,2,3]triazin-4-one | 1153645-41-0

中文名称
——
中文别名
——
英文名称
3-[2-(1,4-diaza-bicyclo[3.2.2]non-4-yl)-pyrimidin-5-yl]-3H-benzo[d][1,2,3]triazin-4-one
英文别名
3-[2-(1,4-diaza-bicyclo[3.2.2]non-4-yl)-pyrimidin-5-yl]-3H-benzo[d][1.2.3]triazin-4-one;3-[2-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)pyrimidin-5-yl]-1,2,3-benzotriazin-4-one
3-[2-(1,4-diaza-bicyclo[3.2.2]non-4-yl)-pyrimidin-5-yl]-3H-benzo[d][1,2,3]triazin-4-one化学式
CAS
1153645-41-0
化学式
C18H19N7O
mdl
——
分子量
349.395
InChiKey
BRIXVAZXRXDDGA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    568.4±60.0 °C(predicted)
  • 密度:
    1.53±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    26
  • 可旋转键数:
    2
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    77.3
  • 氢给体数:
    0
  • 氢受体数:
    7

反应信息

  • 作为反应物:
    描述:
    3-[2-(1,4-diaza-bicyclo[3.2.2]non-4-yl)-pyrimidin-5-yl]-3H-benzo[d][1,2,3]triazin-4-one盐酸 作用下, 以 乙醇 为溶剂, 生成 3-[2-(1,4-diaza-bicyclo[3.2.2]non-4-yl)-pyrimidin-5-yl]-3H-benzo[d][1,2,3]triazin-4-one hydrochloride
    参考文献:
    名称:
    [EN] N-OXIDES OF DIAZABICYCLONONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE
    [FR] N-OXYDES DE DÉRIVÉS DE DIAZABICYCLONONYLE PYRIMIDINE ET LEUR UTILISATION MÉDICALE
    摘要:
    这项发明涉及某些二氮杂双环壬基嘧啶衍生物的新型N-氧化物及其在制备药物组合物中的应用。该发明的化合物被发现是胆碱能受体的配体,同时也是单胺受体和转运体的调节剂。由于它们的药理特性,该发明的化合物可能对治疗与中枢神经系统(CNS)的胆碱系统、外周神经系统(PNS)、平滑肌收缩、内分泌疾病、神经退行性疾病、炎症、疼痛以及化学物质滥用终止引起的戒断症状等各种疾病或疾病具有用处。
    公开号:
    WO2010084184A1
  • 作为产物:
    参考文献:
    名称:
    [EN] NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE
    [FR] NOUVEAUX DÉRIVÉS DE 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINE ET LEUR UTILISATION MÉDICALE
    摘要:
    这项发明涉及到新型1,4-二氮杂双环[3.2.2]壬基嘧啶衍生物的化学式(I)及其在制备药物组合物中的应用。该发明的化合物被发现是毒蕈碱乙酰胆碱受体的胆碱能配体,同时也是单胺受体和转运体的调节剂。由于它们的药理特性,该发明的化合物可能对治疗与中枢神经系统(CNS)的胆碱能系统、外周神经系统(PNS)、平滑肌收缩、内分泌疾病、神经退行性疾病、炎症、疼痛以及由于滥用化学物质终止而引起的戒断症状等各种疾病或紊乱具有用处。
    公开号:
    WO2009062988A1
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE<br/>[FR] NOUVEAUX DÉRIVÉS DE 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINE ET LEUR UTILISATION MÉDICALE
    申请人:NEUROSEARCH AS
    公开号:WO2009062988A1
    公开(公告)日:2009-05-22
    This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives of formula (I) and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
    这项发明涉及到新型1,4-二氮杂双环[3.2.2]壬基嘧啶衍生物的化学式(I)及其在制备药物组合物中的应用。该发明的化合物被发现是毒蕈碱乙酰胆碱受体的胆碱能配体,同时也是单胺受体和转运体的调节剂。由于它们的药理特性,该发明的化合物可能对治疗与中枢神经系统(CNS)的胆碱能系统、外周神经系统(PNS)、平滑肌收缩、内分泌疾病、神经退行性疾病、炎症、疼痛以及由于滥用化学物质终止而引起的戒断症状等各种疾病或紊乱具有用处。
  • N-OXIDES OF DIAZABICYCLONONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE
    申请人:Peters Dan
    公开号:US20120004215A1
    公开(公告)日:2012-01-05
    This invention relates to novel N-oxides of certain diazabicyclononyl pyrimidine derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
    本发明涉及某些二氮杂双环壬基嘧啶衍生物的新型N-氧化物及其在制造药物组合物方面的应用。本发明的化合物被发现是尼古丁乙酰胆碱受体的胆碱能配体和单胺类受体和转运蛋白的调节剂。由于其药理学特性,本发明的化合物可用于治疗与中枢神经系统(CNS)的胆碱能系统、外周神经系统(PNS)、平滑肌收缩相关的疾病或疾患、内分泌疾病或疾患、神经退行性疾病或疾患、炎症、疼痛以及由于滥用化学物质而引起的戒断症状等各种不同疾病或疾患。
  • NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE
    申请人:Peters Dan
    公开号:US20100298307A1
    公开(公告)日:2010-11-25
    This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives of formula (I) and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
    本发明涉及一种新型的1,4-二氮杂双环[3.2.2]壬基嘧啶衍生物(I式),以及它们在制造药物组成物方面的应用。本发明的化合物被发现是烟碱乙酰胆碱受体的胆碱能配体,以及单胺类受体和转运体的调节剂。由于它们的药理特性,本发明的化合物可能对治疗与中枢神经系统(CNS)和周围神经系统(PNS)的胆碱能系统相关的疾病或疾病,平滑肌收缩相关的疾病或疾病,内分泌疾病或疾病,神经退行性疾病或疾病,炎症相关的疾病或疾病,疼痛以及由于化学物质滥用终止而引起的戒断症状等多种疾病或疾病具有用处。
  • EP2209783B1
    申请人:——
    公开号:EP2209783B1
    公开(公告)日:2016-03-16
  • US8343960B2
    申请人:——
    公开号:US8343960B2
    公开(公告)日:2013-01-01
查看更多

同类化合物

苯并咪唑并[1,2-C][1,2,3]苯并三嗪 硫代磷酸 O,O-二甲基 S-((4-氧代-1,2,3-苯并三嗪-3(4H)-基)甲基)酯 益棉磷 吗林那宗 保棉磷 N,N,N',N'-四甲基-O-(3,4-二氢-4-氧代-1,2,3-苯并三嗪-3-基)脲四氟硼酸盐(TDBTU) 8-甲氧基苯并[D][1,2,3]三嗪-4(3H)-酮 7-甲硫基-8,9,10-三氮杂双环[4.4.0]癸-1,3,5,7,9-五烯 7-乙氧基-6-甲氧基-4-(4-三氟甲基苯胺基)-1,2,3-苯并三嗪 7-乙氧基-6-甲氧基-4-(3-三氟甲基苯胺基)-1,2,3-苯并三嗪 7-乙氧基-4-(4-氟-3-三氟甲基苯胺基)-6-甲氧基-1,2,3-苯并三嗪 7-乙氧基-4-(3-氟-4-溴苯胺基)-6-甲氧基-1,2,3-苯并三嗪 7-乙氧基-4-(2-氟苯胺基)-6-甲氧基-1,2,3-苯并三嗪 6-硝基-1,2,3-苯并三嗪-4(1H)-酮2-氧化物 6-甲氧基-4-(4-氟苯胺基)-7-戊氧基-1,2,3-苯并三嗪 6-氟苯并[D][1,2,3]三嗪-4(1H)-酮 6-氟-3-羟基-1,2,3-苯并三嗪-4-酮 5-氯苯并[D][1,2,3]三嗪-4(3H)-酮 5-氟苯并[D][1,2,3]三嗪-4(3H)-酮 4-(4-甲氧基苯基)-1,2,3-苯并三嗪 4-(4-溴-3-氟苯胺基)-6-甲氧基-7-戊氧基-1,2,3-苯并三嗪 4-(3-氯-4-氟苯基氨基)-苯并[d] [1,2,3]三嗪 4-(3,5-二氟苯胺基)-6-甲氧基-7-戊氧基-1,2,3-苯并三嗪 3-苯基-1,2,3-苯并三嗪-4(3H)-酮 3-羟基甲基-4-酮苯并-1,2,3-噻嗪 3-羟基-8-(三氟甲基)苯并[D][1,2,3]三嗪-4(3H)-酮 3-羟基-7-甲基-1,2,3-苯并三嗪-4-酮 3-羟基-6-甲基苯并[D][1,2,3]三嗪-4(3H)-酮 3-羟基-1,2,3-苯并三嗪-4(3H)-酮 3-甲基苯并三嗪-4-酮 3-环己基-1,2,3-苯并三嗪-4-酮 3-氯甲基-3-苯并噻嗪-4(3H)-酮 3-哌啶-4-基-3H-苯并[d] [1,2,3]三嗪-4-酮 3-吡啶-2-基-1,2,3-苯并三嗪-4-酮 3-丙-2-烯基-1,2,3-苯并三嗪-4-酮 3-丁氧基-1,2,3-苯并三嗪-4-酮 3-[(甲氧基-甲硫基磷酰)巯基甲基]-1,2,3-苯并三嗪-4-酮 3-(氯甲氧基)-1,2,3-苯并三嗪-4-酮 3-(哌啶-4-基)苯并[D][1,2,3]三嗪-4(3H)-酮盐酸盐 3-(二乙氧基邻酰氧基)-1,2,3-苯并三嗪-4-酮 3-(二乙氧基磷酰硫基甲基)-1,2,3-苯并三嗪-4-酮 3-(4-溴苯基)-1,2,3-苯并三嗪-4(3H)-酮 3-(4-氧代-1,2,3-苯并三嗪-3(4H)-基)丙酸 3-(2-苯基乙烯基)-1,2,3-苯并三嗪-4-酮 3-(2-甲基吡唑-3-基)-1,2,3-苯并三嗪-4-酮 3-(2-溴苯基)-1,2,3-苯并三嗪-4-酮 3-(1-乙氧基乙基)-1,2,3-苯并三嗪-4-酮 3,4-二氢-4-亚氨基-3-丙基-1,2,3-苯并三嗪 2-(内-5-降冰片烯-2,3-二羧酰亚胺)-1,1,3,3-四甲基脲六氟磷酸盐 2-(4-氧代-4H-苯并[d] [1,2,3]三嗪-3-基)-苯甲酸